8-K

UNITED STATES

 SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

____________

FORM 8-K

CURRENT REPORT

     PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) November 26, 2014

CHROMADEX CORP.

 (Exact name of registrant as specified in its charter)

Delaware	000-53290	26-2940963
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

10005 Muirlands Boulevard, Suite G, Irvine, California, 92618

(Address of principal executive offices, including zip code)

(949) 419-0288

 (Registrant's telephone number, including area code)

Copies to:

Harvey Kesner, Esq.

61 Broadway, 32nd Floor

New York, New York 10006

Phone: (212) 930-9700

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 1.01        ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT

ITEM 2.01        COMPLETION OF ACQUISITION OR DISPOSITION OF ASSETS

 On November 26, 2014, ChromaDex Corporation, a Delaware corporation (the “Company”), pursuant to a Transfer and Notice of Conversion, assigned 108,676 of its 670,658 series I preferred shares (the “Preferred Shares”) of NutriSci International, Inc. (“NS”) to Alpha Capital Anstalt and 10,868 Preferred Shares to Palladium Capital Advisors, LLC. The Transfer and Notice of Conversion amended that certain Assignment and Escrow Agreement by and among the Company, Alpha Capital Anstalt NS, Britlor Health and Wellness, Inc. and Grushko & Mittman, P.C., effective as of December 27, 2013, to allow for such assignments. Also on November 26, 2014, the Company converted its remaining 551,114 Preferred Shares into 2,204,456 Class A common shares of NS (the “Common Shares”) and sold the 2,204,456 Common Shares to Emprise Capital Corporation for a purchase price of $749,514.80 pursuant to the terms of a Share Transfer Agreement.

 The assignments and sale described above occurred immediately prior to the consummation of an agreement between NS and Disani Capital Corp. (“Disani”) pursuant to which Disani acquired NS (the “Amalgamation”).  Upon the closing of the Amalgamation, Alpha Capital Anstalt, Palladium Capital Advisors, LLC and Emprise Capital Corporation, as the new holders of NS securities, were entitled to receive an aggregate of 4,560,474 units of Disani securities.

 The foregoing is a summary of the material terms of the Transfer and Notice of Conversion and the Share Transfer Agreement and does not purport to be complete. These agreements shall be attached as exhibits to the Company’s Annual Report on Form 10-K for the fiscal year ended January 3, 2015 and you should read them in their entirety.

ITEM 7.01        REGULATION FD DISCLOSURE

 On December 3, 2014, the Company issued a press release announcing, among other things, the disposition of the NS securities.  A copy of the press release is appended hereto as Exhibit 99.1 and is incorporated herein by reference.

 The information disclosed under this Item 7.01, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document pursuant to the Securities Act, except as expressly set forth in such filing.

ITEM 9.01        FINANCIAL STATEMENTS AND EXHIBITS

(d)        Exhibits.

Exhibit No.	Description
99.1	Press Release

SIGNATURES

                    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: December 3, 2014

CHROMADEX CORP.
By:	/s/ Frank L. Jaksch Jr.
Name:	Frank L. Jaksch Jr
Title:	Chief Executive Officer

                                                                                   .

EX-99

Exhibit 99.1

ChromaDex^® Receives $750,000 Cash from Previous Sale of its BluScience™ Line

IRVINE, Calif., Dec. 3, 2014 – ChromaDex^® Corp. (OTCQX: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries, announced today that it has received a cash payment of approximately $750,000 for the shares of NeutriSci International Inc. (“NeutriSci”), that the company received as part of its prior transaction with NeutriSci.

In March 2013, ChromaDex closed on the sale of its BluScience™ consumer product line to NeutriSci. The sale of the BluScience™ line allowed ChromaDex to hone its focus on growing the sales of its ingredient business, as well as accelerating the development of its novel ingredient pipeline. ChromaDex expects to continue to generate revenue from this relationship through its 6 percent royalty agreement on future net sales of BluScience™ products and its supply agreement with NeutriSci on ChromaDex’s patented pTeroPure® pterostilbene ingredient.

Frank Jaksch, Jr., CEO and co-founder of ChromaDex, commented, “The $750,000 resulting from our 2013 sale of the BluScience™ line strengthens our balance sheet and, in particular, our cash position.  Coupled with our recent $5.0 million in debt financing from Hercules Technology Growth Capital, we believe that we are well positioned to fund our operations at least through 2015, as our business transitions to cash flow positive and profitability.”

ChromaDex’s product portfolio includes scientific ingredients that have demonstrated multiple health benefits, including NIAGEN® and PURENERGY®, both of which are undergoing clinical trials. In its most recent quarterly earnings report, ChromaDex reported a 160 percent year-over-year increase in its ingredient sales.

 “We continue to see strong demand for our novel ingredient technologies, especially our NIAGEN® nicotinamide riboside, and we expect both revenue growth and business development activity to continue to increase in 2015,” Jaksch added.

About ChromaDex:

ChromaDex is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model that utilizes its wholly owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (as Spherix Consulting). The company provides seamless science-based solutions to the nutritional supplement, food and beverage, animal health, cosmetic and pharmaceutical industries. The ChromaDex ingredient technologies unit includes products backed with extensive scientific research and intellectual property. Its ingredient portfolio includes pTeroPure® pterostilbene; ProC3G^®, a natural black rice containing cyanidin-3-glucoside; PURENERGY®, a caffeine-pTeroPure co-crystal; and NIAGEN®, its recently launched branded nicotinamide riboside, a novel next-generation B vitamin. To learn more about ChromaDex, visit www.chromadex.com.

Forward-Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as “expects”, “anticipates”, “intends”, “estimates”, “plans”, “potential”, “possible”, “probable”, “believes”, “seeks”, “may”, “will”, “should”, “could” or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company’s business. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended December 28, 2013, the Company’s Quarter Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

ChromaDex Company Contact:

Laura Kelly, Executive Assistant 949-419-0288laurak@chromadex.com

##END##